Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

This is the logo of the provider
AASLD 2026 5 - 9 November 2026

Efruxifermin drives multidimensional histologic improvement in compensated cirrhosis: An AI-based analysis from the SYMMETRY randomized controlled trial​

Authors :

Mazen Noureddin1; Jӧrn Schattenberg2; Vlad Ratziu3; Ylaine Gerardin4; Alyson R. Warr4; Jacqueline Brosnan-Cashman4; Doreen Chan5; Erik J. Tillman5; Reshma Shringarpure5; Mary E. Rinella6

Affiliations
View Details Hide Details
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Keywords
MASH
Congress oral presentation
Fibroblast growth factor
PHASE 2 (RCT)